Auspherix and Domainex Expand Collaboration to Develop New Drugs that Tackle Antibiotic-Resistant Bacterial Infections

Cambridge, UK and Stevenage, UK – 15 September 2015 – Domainex and Auspherix today announce an expansion of their collaboration to develop new drugs to tackle the growing threat of resistance to antibiotics. The programme has been extended through to 2017.

Since initiating the project in 2014, significant progress has been made towards the invention of new compounds with activity against both gram-positive and gram-negative bacteria. The collaboration extension aims both to refine the current chemical series towards selection of novel pre-clinical candidates and to explore potential additional compound series. A team of at least five chemists will be deployed at Domainex providing analytical and medicinal chemistry expertise, working in partnership with Auspherix’s growing R&D team.

Eddy Littler, Chief Executive Officer of Domainex said, “We are very pleased to have expanded our partnership with Auspherix. This is a strong endorsement of the inventiveness, productivity and client-focus of our drug discovery services team. We will undertake further lead optimisation studies to build on the excellent progress made to date. Together with Auspherix, we are focused on the identification of novel pre-clinical drug candidates to address the growing global burden of multi-drug resistant bacterial diseases.”

Alongside the expansion of the medicinal chemistry programme with Domainex, Auspherix is building its UK-based microbiology and management teams at the Stevenage Bioscience Catalyst. It is intensifying discovery research on its initial bacterial disease focus, and intends to explore further the potential in its antibiotic platform.

Professor Ian Charles, co-founder and CSO of Auspherix said, “Having established operations in the UK, our initial programmes are on track and making excellent progress. We believe the novel mechanism of action of our compound series discovered jointly with Domainex’s scientists offers enormous potential for the development of a new arsenal of drugs that will be required to treat the growing numbers of bacterial infections.”

-Ends-

About Auspherix Ltd

Auspherix Ltd has discovered a brand new class of anti-bacterials with a unique profile and novel mechanism of action that could overcome the major global problem of antimicrobial resistance. Its compound series show activity against a broad range of multidrug resistant (MDR) gram-negative and gram-positive bacteria, with PK profiles consistent with their use as antibacterial drugs for a number of indications with high unmet medical need and large market potential.

Based in Stevenage UK (in the Stevenage Bioscience Catalyst facility), the Company was founded in late 2013 based on discoveries made at the ithree institute at the University of Technology Sydney (UTS). The Company has raised AUS$2 million in Seed and Series A1 investments (2013-2014) from Australia’s Medical Research Commercialisation Fund (MRCF) and £6 million in Series A2 round (2015) from the MRCF and the UK’s Imperial innovations plc (AIM IVO).

For further information please visit www.auspherix.com

About Domainex

Domainex Ltd. is a Cambridge-based small-molecule drug discovery company that provides integrated drug discovery services to pharmaceutical, biotechnology and academic partners globally. Services cover a wide span of the drug discovery value chain, from disease target validation to pre-clinical candidate nomination. Domainex’s services include recombinant protein expression and use of its proprietary technology platform, Combinatorial Domain Hunting to identify soluble protein fragments for structural biology and assay development. Hit finding activities encompass assay development and screening utilising its Bioassay Builder and LeadBuilder portfolios. The core of the service platform is undertaking multi-parameter medicinal chemistry optimisation of hits and leads under the mantra ‘every compound counts’, which can save up to 30% of average industry time.

Additionally, Domainex is investing in developing its own therapeutic compounds for out-licensing in two specific areas: 1) Inhibitors of the kinases TBK1 & IKK epsilon to treat inflammatory conditions such as COPD and psoriasis; 2) The emerging epigenetic target class of lysine methyltransferases potentially implicated in oncology, where to date Domainex has built a portfolio of drug discovery assets encompassing novel chemical matter, proprietary assays and crystal structures.

For more information please visit www.domainex.co.uk

For more information please contact:

Auspherix

UK and ROW

Roberto Solari, Chairman (UK and RoW)

Roberto.solari@auspherix.com

Tel: +44 (0)20 7594 3116

In Australia

Stephen Thompson, Director

sthompson@brandoncapital.com.au

Tel: +61 (0)404 153 957

Media relations (Instinctif Partners)

Sue Charles / Gemma Howe / Rosanna Forrest

auspherix@instinctif.xom

Tel: +44 (0)20 7866 7860

Domainex

Tom Mander, Chief Operating Officer

tom.mander@domainex.co.uk

Tel: +44 (0)7584 578024

Media Relations (Sciad)

Deborah Cockerill

deborah@sciad.com

M: +44 (0)7930 317729

James Motteram

james@sciad.com

Tel: +44(0)203 773 9580

Auspherix Expands Board of Directors and Scientific Advisory Board

Stevenage, UK, 22 July 2015 – Auspherix Limited (UK), an early stage anti-infectives company, has announced that it has expanded and strengthened its Board and Scientific Advisory Board with the appointments of Dr Jared Silverman as Non-Executive Director and Scientific Advisor, and Professor David Livermore as a Scientific Advisor.

Dr Silverman’s career has focused on the discovery and development of novel antibiotics to treat serious, drug resistant infections in the hospital setting. US-based, he is currently VP of Research at VL32, following 18 years at Cubist Pharmaceuticals. He has two decades of experience in converting basic science into clinically and commercially useful data to guide drug development, patient treatment and marketing strategy. His research has contributed to the discovery of three novel antibiotics that entered clinical development.

Professor Livermore brings a wealth of knowledge and expertise to the Company, with over 35 years in the sector and a long track record of research and publications on the evolution and epidemiology of antibiotic resistance, particularly b-lactamases. Currently Professor of Medical Microbiology at the University of East Anglia (UEA), he serves on the UK Government’s Antimicrobial Resistance & Healthcare Associated Infection Advisory Committee. Earlier in his career he spent 14 years with the Public Health Laboratory Service (now Public Health England), becoming Director of its Antibiotic Resistance Monitoring and Reference Laboratory, and 17 years at the London Hospital Medical College.

Commenting on the new appointments, Dr Roberto Solari, Non-Executive Chairman of Auspherix, said: “Being able to attract individuals of the quality and international standing of Jared and David underlines the potential that exists within Auspherix. Their decades of experience and achievement in the anti-infectives arena will be invaluable in helping to guide our discovery and development efforts.

“These appointments, along with other recent additions to our senior team, our move to the UK and securing £6m in venture financing means that we are well positioned to progress our discoveries of a new class of antibiotics with novel mechanisms of action. Finding ways to address the ever increasing issue of antibiotic resistance is critical to future medicine and we are pleased to be playing a role in that endeavor.”

Auspherix is actively recruiting to expand its science and management teams.

-Ends-

Notes for editors

About Auspherix Ltd

Auspherix Ltd has discovered a brand new class of antibacterials with a unique profile and novel mechanism of action that could overcome rising problems of resistance to current antibiotics. Its compound series show activity against a broad range of multidrug resistant (MDR) important Gram-negative and Gram-positive bacterial infections, with PK profiles consistent with their use as antibacterial drugs for a number of indications with high unmet need and large market potential.

Based in Stevenage UK (in the Stevenage Bioscience Catalyst facility), the Company was founded in late 2013 based on discoveries made at the ithree institute at the University of Technology Sydney (UTS). The Company has raised AUS $2million in Seed and Series A1 investments (2013-2014) from Australia’s Medical Research Commercialisation Fund (MRCF) and £6 million in Series A2 round (2015) from the MRCF and the UK’s Imperial innovations plc (AIM IVO).

For further information please visit www.auspherix.com

About Dr Jared Silverman

Dr Silverman’s career has focused on the discovery and development of novel antibiotics to treat serious, drug resistant infections in the hospital setting. US-based, he is currently VP of Research at VL32, following 18 years at Cubist Pharmaceuticals where he contributed to the discovery of three novel antibiotics that entered clinical development, including as the biology lead for the discovery of Surotomycin, currently in Phase 3 trials for the treatment of C. difficile.  Additionally, Dr Silverman and his collaborators pursued studies into the mechanism of action of the lipopeptide antibiotic daptomycin and the mechanisms of resistance to this clinically important antibiotic. He undertook postdoctoral training at Yale University and has a PhD in Microbiology from Harvard Medical School. Dr. Silverman serves as a member of the UK MRC’s Antimicrobial Resistance steering group.

About Professor David Livermore

Professor Livermore brings a wealth of knowledge and expertise to the Company, with over 35 years in the sector and a long track record of research and publications on the evolution and epidemiology of antibiotic resistance, particularly b-lactamases. Currently Professor of Medical Microbiology at the University of East Anglia (UEA), he serves on the UK Government’s Antimicrobial Resistance & Healthcare Associated Infection Advisory Committee, and has contributed extensively to the Chief Medical Officer for England’s 2011 Annual Report.  Prior to this he spent 14 years with the Public Health Laboratory Service (now Public Health England), becoming Director of its Antibiotic Resistance Monitoring and Reference Laboratory.  Within his current UEA role, he continues to provide sessions to Public Health England as its Lead on Antibiotic Resistance. In his earlier career, Professor Livermore spent 17 years at the London Hospital Medical College.  He has edited for several journals, presently including the International Journal of Antimicrobial Agents.  David has a PhD in Medical Microbiology from the University of London. He consults widely for the pharmaceutical industry.

For more information please contact:

Media Relations – Instinctif Partners

Sue Charles/ Gemma Howe/ Rosanna Forrest

T: +44 (0)20 7457 2020

E: auspherix@instinctif.com

Auspherix

In the UK

Dr Roberto Solari, Chairman

T:  +44 (0)20 7594 3116

E: Roberto.solari@auspherix.com

In Australia

Dr Stephen Thompson, Director of Auspherix and Partner at Brandon Capital (manager of the MRCF)

T +61 (0)3 9657 0700

E: SThompson@brandoncapital.com.au

Auspherix Appoints Experienced Anti-Infectives Clinician to Scientific Advisory Board

Auspherix, an early stage anti-infectives company, today announces that it has expanded its Scientific Advisory Board (SAB) with the appointment of highly experienced clinician, Professor William Hope.

William’s career to date has focused on research in antimicrobial pharmacokinetics and pharmacodynamics, mathematic modelling of antimicrobial agents and individualisation of antimicrobial therapy.  He is an NIHR Clinical Scientist and Professor of Therapeutics and Infectious Diseases at The University of Liverpool, UK and was recently appointed as Chair in the Department of Molecular and Clinical Pharmacology at The University of Liverpool. A Fellow of the Royal Australasian College of Physicians and the Royal College Pathologists of Australasia. He was previously Chair in Therapeutics and Infectious Diseases at The University of Manchester. He has a PhD in antimicrobial pharmacology from The University of Manchester.  Alongside his advisory role to Auspherix, William is also Scientific Advisor to the ESCMID Fungal Infection Study Group, Secretary to the EUCAST Antifungal Susceptibility Testing Sub-Committee and was recently appointed to the ICAAC Program Committee for Antimicrobial Pharmacokinetics, Pharmacodynamics and General Pharmacology.

Founded in 2013, Auspherix is developing a new class of anti-bacterials with a unique profile suggestive of a novel mechanism of action.

Dr Neil Miller, CSO of Auspherix, said: “With his hands on clinical experience, and a depth of knowledge gained during his careers in the anti-infectives space, William’s input and guidance will make an invaluable addition to the insight and steer we get from our SAB as we progress our novel anti-bacterial drug candidates through pre-clinical development towards our first-in-human clinical trial.”

The Auspherix’s SAB is chaired by Professor Ian Charles, co-founder and previously CSO of the Company, and now Director of the Institute of Food Research/Quadram Institute. He has a strong focus on translational research and infectious diseases, and was previously co-founder and CSO of Arrow Therapeutics. As well as new member Professor William Hope, other SAB members are: Auspherix CSO Neil Miller; Auspherix Board member Dr Jared Silverman, VP of Research at VL32 and who contributed to the discovery of three novel antibiotics during his career within Cubist Pharmaceuticals; Dr Alan Naylor, an independent consultant and medicinal chemist with over 30 years of R&D experience within GlaxoSmithKline; and Professor David Livermore, Professor of Medical Microbiology at the University of East Anglia  and serves on the UK Government’s Antimicrobial Resistance & Healthcare Associated Infection Advisory Committee.

-Ends-

Notes to Editors

About Auspherix Ltd

Auspherix Ltd has discovered a novel class of antibacterials with a unique profile suggestive of a novel mechanism of action and therefore offer the potential to address the rising global problem of resistance to current antibiotics. Its compound series show activity against a broad range of multidrug resistant (MDR) important Gram-negative and Gram-positive bacterial infections, with profiles consistent with their use as antibacterial drugs for a number of indications with high unmet need and large market potential.

Based in Stevenage UK (in the Stevenage Bioscience Catalyst facility), the Company was founded in late 2013 based on discoveries made at the ithree institute at the University of Technology Sydney (UTS). The Company has raised AUS $2million in Seed investments (2013-2014) from Australia’s Medical Research Commercialisation Fund (MRCF) and £6 million in Series A round (2015) from the MRCF and the UK’s Imperial innovations plc (AIM IVO).

For more information please contact:

Media Relations – Instinctif Partners

Sue Charles / Gemma Howe / Rosanna Forrest

T: +44 (0)20 7457 2020

E: auspherix@instinctif.com

Auspherix

Dr Neil Miller

T: +44 (0)1438 906755

E: neil.miller@auspherix.com

Auspherix Raises £6Million to Progress its Novel Antibiotics and Establishes UK Operations

Stevenage, UK, 3 June 2015 – In the race to develop new antibiotics with completely new modes of action that might address the growing threat posed by antimicrobial resistance, Auspherix Limited (UK), an early stage anti-infectives company originated in Sydney Australia, has raised £6 million in a Series A venture financing, and is establishing operations on the Stevenage Bioscience Catalyst site just outside of London, UK. New investor Imperial Innovations plc (AIM IVO) led the round alongside Australian founding investor the Medical Research Commercialisation Fund (MRCF).

The investment will be used to fund the Company’s drug discovery programme, expand the experienced management team and recruit a world-class microbiology team. Auspherix aims to progress its novel class of antibacterials, which have a unique profile and novel mechanism of action, through lead optimization to final candidate selection within the next two years. Auspherix’s current lead compounds show activity against a broad range of multidrug resistant (MDR) important Gram-negative and Gram-positive bacterial infections.

The Company was co-founded by Professor Ian Charles and Dr Dagmar Alber during their time together at the ithree institute, UTS, Sydney. Dr Roberto Solari has joined the Board of Directors as its independent non-executive Chairman. Previously, Dr Solari was Vice President in GSK’s UK-based Respiratory Therapy Area, and is currently senior research fellow in the National Heart and Lung Institute, Imperial College London, focusing on respiratory infections. He is also an advisor to Imperial Innovations and Brandon Capital Partners, and is on the board of Heptares and the Science Advisory Board of Astex Pharmaceuticals. Before joining GSK, Dr Solari was CEO of the UK Medical Research Council’s technology transfer arm, MRCT, creating spin out companies such as Heptares and developing an internal drug discovery group. The Company has also appointed Grant Hawthorne, an experienced biotech company director as COO.

Founding venture investor and Auspherix Board member Dr Stephen Thompson, Partner at Brandon Capital Partners, the Australian venture capital firm that manages the MRCF, said: “Auspherix has progressed very rapidly and is now at the stage that building out the team is appropriate. The potential of the Company’s new class of anti-infectives is an extremely exciting opportunity and I am delighted that Imperial innovations has agreed to invest alongside the MRCF to move the programmes forward.”

Commenting on the investment and Auspherix’s potential, Dr Solari said: “Auspherix’s novel chemistry has activity against a broad range of multidrug resistant (MDR) Gram-negative and Gram-positive bacterial infections and the initial pharmacokinetic profile of these compounds is consistent with their use as an antibacterial drug for a number of indications with high unmet need and large market potential.”

Professor Charles, co-founder and CSO said “The need to find new ways to combat infectious diseases becomes more urgent year-on-year as superbugs continue to emerge that are resistant to more and more current antibiotics. Whilst drug discovery is a long road, to have discovered antibacterial compounds with completely novel chemical structures is very exciting and I look
forward to working with the new team as we move our discoveries forward towards the clinic
.”

The Company anticipates appointing a CEO within the coming months, and is building out its Stevenage-based R&D team. It will pursue a flexible investment and partnering model aimed at maximizing the speed with which it can develop and commercialize its novel antibiotic drug candidates.

-Ends-

Notes for editors

About Auspherix Ltd
Auspherix Ltd has discovered a brand new class of antibacterials with a unique profile and novel mechanism of action that could overcome rising problems of resistance to current antibiotics. Its compound series show activity against a broad range of multidrug resistant (MDR) important Gram-negative and Gram-positive bacterial, with PK profiles consistent with their use as antibacterial drugs for a number of indications with high unmet need and large market potential.

Based in Stevenage UK (in the Stevenage Bioscience Catalyst facility), the Company was founded in late 2013 based on discoveries made at the ithree institute at the University of Technology Sydney (UTS). The Company has raised AUS$2 million in in Seed and Series A1 investments (2013-2014) from Australia’s Medical Research Commercialisation Fund (MRCF) and £6 million in Series A2 round (2015) from the MRCF and the UK’s Imperial innovations plc (AIM IVO)).

For further information please visit www.auspherix.com.

About Imperial innovations
Imperial Innovations Group plc creates, builds and invests in pioneering technologies developed from the academic research within the ‘Golden Triangle’ broadly bounded by London, Cambridge and Oxford, which is home to the UK’s four leading research-intensive universities.

This area is home to many new technology companies through its proximity to the academic communities of Imperial College London, the University of Cambridge, the University of Oxford and University College London, as well as other leading research institutions.

Imperial College London, the University of Cambridge, the University of Oxford and University College London collectively have research income of £1.4 billion per annum and are ranked as four of the top ten Universities in the world (source: QS World University Rankings 2014/15).

Innovations supports scientists and entrepreneurs in the commercialisation of their ideas through the licensing of intellectual property, by leading the formation of new companies, providing facilities in the early stages, providing investment and encouraging co-investment to accelerate development, providing operational expertise and recruiting high-calibre management teams. It also runs an incubator in London that is the initial home for many of its technology spin-outs.

Since admission of its shares to trading on AIM in 2006, Innovations has raised more than £346.0 million of equity from investors, which has enabled it to invest in some of the most exciting spin-outs to come out of UK academic research. In addition, the Group has a £30.0 million loan facility from the European Investment Bank (EIB) for investment in biotech and therapeutics businesses.

During the period from admission on AIM up until 31 January 2015, Innovations has invested a total of £198.3 million across its portfolio companies, which have raised collectively investment of £926.8 million rising to £1.0 billion including post period end investments and commitments.

For further information please visit www.imperialinnovations.co.uk.

About The Medical Research Commercialisation Fund (MRCF)
The MRCF Collaboration, managed by Brandon Capital Partners, brings together over 50 of Australia’s leading medical research institutes and research hospitals in an innovative investment collaboration. The MRCF provides dedicated investment funding to support the commercialisation of early-stage medical research discoveries that originate from its members.

AU$200m MRCF3 fund launched in 2015 is supported by AustralianSuper, StatewideSuper, HESTA and HOSTPLUS industry superannuation funds. The MRCF’s first two funds, the MRCF Trust and MRCF IIF LP, totalling AU$51m were established in 2007 and 2011 and were supported by AustralianSuper, StatewideSuper and the Australian Government through its Innovation Investment Fund (IIF) program. The MRCF acknowledges support from the State Governments of Victoria, New South Wales, Western Australia, Queensland and South Australia.

For further information please visit www.mrcf.com.au andwww.brandoncapital.com.au.

For more information please contact:

Media Relations – Instinctif Partners
Sue Charles/ Gemma Howe/ Rosanna Forrest
T: +44 (0)20 7457 2020
E: auspherix@instinctif.com

Auspherix

In the UK
Dr Roberto Solari, Chairman
T: +44 (0)20 7594 3116
E: Roberto.solari@auspherix.com

In Australia
Dr Stephen Thompson, Director of Auspherix and Partner at Brandon Capital (manager of the MRCF)
T +61 (0)3 9657 0700
E: SThompson@brandoncapital.com.au

Please click on the link below to download the full Press Release:-

Auspherix Raises £6Million to Progress its Novel Antibiotics and Establishes UK Operations

Auspherix secures additional AU$1million from MRCF to advance its antibiotic pipeline: Highly experienced team secured

  • Auspherix secures additional AU$1million from MRCF to advance its antibiotic pipeline
  • Highly experienced team secured

Sydney, Australia – Auspherix Pty Ltd, an early stage anti-infectives company developing novel antibiotics to treat resistant bacterial disease has secured a further AU$1 million in a series A financing from Australia’s Medical Research Commercialisation Fund (MRCF), to progress its antibacterial compounds through development studies.

In less than 12 months since its foundation 2013, Auspherix has identified a number of antibacterial compounds with broad spectrum activity against a panel of clinical isolates of antibiotic resistant Gram-positive and Gram-negative bacteria. Through a hit to lead programme conducted in collaboration with Domainex, Auspherix now has a better understanding of the SAR necessary to target the organisms and has improved the antibiotic activity of the initial compounds. The new investment will be used to further refine the lead compound series, and to screen these in in vivo models in collaboration with Evotec (previously Euprotec).

Auspherix has adopted a virtual business model with research being directed by Professor Ian Charles CSO and founder of Auspherix, who is Director of the ithree institute at the University of Technology Sydney (UTS). The founding intellectual property behind Auspherix was in-licensed from the ithree institute based on research led by Professor Charles, together with Dr Dagmar Alber, ithree Senior Research Fellow. Professor Charles and Dr Alber previously worked together successfully at Arrow Therapeutics as CSO and head of virology respectively.

The scientific team has been further strengthened by the appointment of Dr Ian Holmes as head of chemistry alongside Dr Alber as head of biology. Dr Holmes is an experienced medicinal chemist and pre-clinical project leader with a proven track record of program milestone delivery in large pharma and biotech environments. Past positions include Director of Medicinal Chemistry at Cancer Therapeutics CRC, Melbourne, Australia and prior to that at GSK.

Auspherix has appointed two independent consultants to advise the Company: Dr Alan Naylor and Dr Mike Tarbit. Prior to his consulting career Dr Naylor spent 30 years in medicinal chemistry at GSK, latterly as Vice President, Head of Strategy and Operations and Director of Medicinal Chemistry at a UK-based Centre of Excellence in Drug Discovery. Dr Tarbit’s career has spanned biotech and pharma, including at Inpharmatica, ArQule, GSK and Pfizer.

Professor Charles said “It is now widely recognized that we desperately need to find new ways to combat infectious diseases including resistant bacterial infections. At Auspherix we are making rapid advances in optimizing potential antibacterial compounds with completely novel chemical structures which, if successful, will deliver the drugs needed to keep the threat from superbugs in check.”

Commenting on the second tranche of investment into Auspherix, Stephen Thompson, Chairman of Auspherix and Partner at Brandon Capital, the venture capital firm that manages the MRCF said “Auspherix has made astonishing progress in less than a year, successfully achieving all of the key milestones. The potential to bring a new class of anti-infectives to market is an extremely exciting opportunity and we are pleased to have made an additional investment into the Company.”

Subject to meeting near-term milestones, Auspherix will rapidly seek further investment and/or industry partnerships to move its novel antibiotics into pre-clinical and clinical development.

-Ends-

Notes for editors

About Auspherix Pty Ltd

Auspherix Pty Ltd is an early-stage anti-infectives company developing novel antibiotics to treat resistant bacterial diseases. It was spun out from the ithree institute at the University of Technology Sydney (UTS) in 2013. It has secured a total of with AU$2 million in start-up funding from Australia’s Medical Research Commercialisation Fund (MRCF).

Incorporated in Sydney, Australia, Auspherix has adopted a virtual business model with research being conducted at universities in Australia and the UK, and by UK-based companies Domainex and Evotec.

About the ithree institute

The ithree institute at the University of Technology Sydney (UTS) brings together an internationally competitive team focused on addressing key challenges in the understanding and control of infectious diseases in humans and animals. The institute’s innovative science uses a systems biology approach to develop a greater insight into basic biology and its application to the diagnosis, treatment and prevention of infectious diseases. The ithree institute joined the MRCF in 2011 and has secured investment from MRCF for two companies: Helmedix (AU$1.25 million) and Auspherix (AU$2 million).

For further information please visit www.ithreeinstitute.uts.edu.au

About The Medical Research Commercialisation Fund (MRCF)

The $51 million Medical Research Commercialisation Fund (MRCF) is an innovative investment collaboration established in 2007 and managed by Brandon Capital Partners (www.brandoncapital.com.au). The MRCF invests in early stage development and commercialisation opportunities emanating from its member Australian medical research institutes and allied research hospitals, which includes the ithree institute at UTS in Sydney. The MRCF IIF, LP fund is supported by AustralianSuper, StatewideSuper and the Australian Government through its Innovation Investment Fund (IIF) program. The MRCF Collaboration also acknowledges the support of the State Governments of Victoria, New South Wales, Western Australia, Queensland and South Australia.

For further information please visit www.mrcf.com.au

For more information please contact:

Auspherix/MRCF

Stephen Thompson

Director of Auspherix and Partner at Brandon Capital (manager of the MRCF)

SThompson@brandoncapital.com.au

T +61 (0)404 153 957

Media Relations

Sue Charles / Gemma Howe / Rosanna Forrest

Instinctif Partners

auspherix@instinctif.com

D +44 (0)20 7457 2020

Please click on the link below to download the full Press Release:-

Auspherix secures additional AU$1million from MRCF to advance its antibiotic pipeline: Highly experienced team secured

Auspherix and Domainex Announce Collaboration to Develop New Drugs to Treat Antibiotic-resistant Bacterial Infections

Cambridge, UK and Sydney, Australia –  Domainex Ltd. and Auspherix Pty Ltd today announced a collaboration that will progress Auspherix’s novel anti-infective drug discovery programme towards the nomination of a clinical candidate. Auspherix intends to develop much-needed new drugs to fight the increasing problem of antibiotic-resistant bacterial infections, which have been widely reported as one of the most significant threats to patients’ safety across the world.*

Auspherix, an early-stage anti-infectives company, has in-licensed intellectual property from the ithree institute at the University of Technology Sydney (UTS) with the intention of developing antibiotics with novel mechanisms of action to treat resistant bacterial disease. The company was established in 2013 as a spin out from the ithree institute by its Director Professor Ian Charles and Senior Research Fellow Dr Dagmar Alber with venture funding from Australia’s Medical Research Commercialisation Fund (MRCF). Professor Charles and Dr Alber have previously enjoyed success working together at the UK anti-infectives company Arrow Therapeutics, which was also co-founded by Professor Charles.

“We are seeing increasing numbers of cases of drug-resistant bacteria around the world, driven by cumulative overuse of antibiotics. With the rise of resistant superbugs, we desperately need to find new ways to combat infectious diseases” Professor Charles said, adding “we selected Domainex as our medicinal chemistry partner for this project, as its scientists are highly-experienced in the development of novel anti-infectives and we are looking forward to nominating a clinical candidate for progression into patients in due course.”

Domainex, a UK-based company that provides integrated drug discovery services to progress research projects from hit identification to proof of concept, is deploying its highly-experienced team of medicinal chemists to build on initial work undertaken by Auspherix. The small-molecule drug leads identified by Auspherix are being further refined with the help of the Domainex team to deliver effective novel antibiotic drug candidates suitable for progression to the clinic.

Eddy Littler, Chief Executive Officer of Domainex said, “We are thrilled to be working with Auspherix and combining their teams’ extensive expertise in antibacterial research with Domainex’s impressive track record in drug discovery. It has already proven to be a strong and fully integrated collaboration, and we are confident that our joint success will make a significant contribution to the treatment of antibacterial diseases.”

* Each year in the United States, at least 2 million people become infected with bacteria that are resistant to antibiotics and at least 23,000 people die each year as a direct result of these infections [Centers for Disease Control and Prevention –http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf].

– ENDS –

Notes to editors

About Auspherix Pty Ltd

Auspherix Pty Ltd is an early-stage anti-infectives company developing novel antibiotics to treat resistant bacterial diseases. It was spun out from the ithree institute at the University of Technology Sydney (UTS) in 2013, with AU$1million in start-up funding from the Medical Research Innovation Fund (MRCF).

About the ithree institute

The ithree institute at the University of Technology Sydney (UTS) brings together an internationally competitive team focused on addressing key challenges in the understanding and control of infectious diseases in humans and animals. The institute’s innovative science uses a systems biology approach to develop a greater insight into basic biology and its application to the diagnosis, treatment and prevention of infectious diseases.

For further information please visit www.ithreeinstitute.uts.edu.au

About Domainex

Domainex is a drug discovery company that provides integrated drug discovery services, including computational and medicinal chemistry, DMPK testing, biochemical and cell-based assay development, to pharmaceutical and biotechnology companies across the world. It is focussed on efficiency in drug discovery, typically managing to cut programme duration by 30% through use of its proprietary technology platform, Combinatorial Domain Hunting, and a focussed approach to compound design.
Domainex is based on the Cambridge Science Park, England and has offices in the London Bioscience Innovation Centre.
For more information please visit www.domainex.co.uk

For more information please contact:

Domainex

Joanne McCudden

Head of Business Development

Joanne.mccudden@domainex.co.uk

+44 (0)7775 437107

Media Relations

Sylvie Berrebi

sylvie@sciad.com

+44 (0)7795 197271

Deborah Cockerill

deborah@sciad.com

+44 (0)7930 317729

Auspherix

Stephen Thompson

Director of Auspherix

sthompson@brandoncapital.com.au

+61 (0)404 153 957

Media Relations

Sue Charles / Gemma Howe / Rosanna Forrest

Instinctif Partners

auspherix@instinctif.com
+44 20 7457 2020

Please click on the link below to download the full Press Release:-

Auspherix and Domainex Announce Collaboration to Develop New Drugs to Treat Antibiotic-resistant Bacterial Infections

Auspherix Welcomes O’Neill Report on Drug Resistant Infections

Auspherix, an early stage anti-infectives company, today welcomes the O’Neill report on antimicrobial resistance “Tackling Drug-Resistant Infections Globally” which calls for large pharmaceutical companies to participate in the development of new treatments. Research has almost halted in the past 25 years because antibiotics are expensive to develop and provide relatively small returns.

Dr Neil Miller, CSO of Auspherix said, “We chose to establish operations in the UK in order to access the pool of highly qualified scientific talent and to leverage the supportive environment for entrepreneurs and the biotech sector that the UK government has encouraged. Our lead programmes are making excellent progress and we believe the antimicrobial profile of our proprietary compound series offers enormous potential for the development of a new arsenal of drugs that will be required to treat the growing numbers of resistant bacterial infections.”

Read the full report here.

MRCF Invests AU$1m in Antibiotics Start-Up Auspherix

Sydney, Australia – Auspherix Pty Ltd, an early stage anti-infectives company developing novel antibiotics to treat resistant bacterial disease was launched today with AU$1 million in start-up financing from Australia’s Medical Research Commercialisation Fund (MRCF).

Auspherix will in-license intellectual property from the ithree institute at the University of Technology Sydney (UTS), emerging from research led by Professor Ian Charles, Director of the ithree institute together with Dr Dagmar Alber, ithree Senior Research Fellow. Professor Charles and Dr Alber previously worked together at the successful UK anti-infectives company Arrow Therapeutics, of which Professor Charles was a co-founder.

The ithree team has been exploring new ways to treat bacterial infections that have become resistance to currently available antibiotics. It has used a library screening approach to identify drugs with novel mechanisms of action as antibiotics.

The initial investment by the MRCF will be used for a lead optimization programme to improve the antibiotic activity and bioavailability of drugs that have been identified through the screening programme undertaken at ithree, and to establish initial safety and efficacy data in in vivo models. The Company will adopt a virtual business model with research being undertaken by the ithree founding scientists, as well as through partners in the UK.

Commenting on the investment in the new company, Stephen Thompson, Director of Auspherix and Partner at Brandon Capital, the venture capital firm that manages the MRCF said “Auspherix is an early but exciting opportunity. The approach that the ithree scientists have taken could help to bring a new class of anti-infectives to market.”

“With the rise of resistant superbugs, we desperately need to find new ways to combat infectious diseases and I am hopeful, based on our early findings, that research from the ithree institute will make a contribution to that urgent quest” added Professor Charles.

Subject to meeting milestones, Auspherix will seek further investment or industry partnerships to move the novel antibiotics into pre-clinical and clinical development, potentially for broad spectrum use.

This is the second investment by MRCF in technology emerging from the ithree institute. It invested AU$1.25 million in Helmedix in February 2013.

The ithree institute was launched in 2010 and joined the MRCF in 2011.

-Ends-

Notes for editors

About the ithree institute

The ithree institute at the University of Technology Sydney (UTS) brings together an internationally competitive team focused on addressing key challenges in the understanding and control of infectious diseases in humans and animals. The institute’s innovative science uses a systems biology approach to develop a greater insight into basic biology and its application to the diagnosis, treatment and prevention of infectious diseases.

For further information please visit www.ithreeinstitute.uts.edu.au

About The Medical Research Commercialisation Fund (MRCF)

The $51 million Medical Research Commercialisation Fund (MRCF) Collaboration is an innovative investment collaboration established in 2007 and managed by Brandon Capital Partners (www.brandoncapital.com.au). The MRCF invests in early stage development and commercialisation opportunities emanating from its member Australian medical research institutes and allied research hospitals, which includes the ithree Institute @ UTS in Sydney. The MRCF IIF, LP fund is supported by AustralianSuper, StatewideSuper and the Australian Government through its Innovation Investment Fund (IIF) program. The MRCF Collaboration also acknowledges the support of the State Governments of Victoria, New South Wales, Western Australia and Queensland.

For further information please visit www.mrcf.com.au

For more information please contact:

Sue Charles / Gemma Howe / Rosanna Forrest

Instinctif Partners

auspherix@instinctif.com

D +44 (0)20 7457 2020

Please click on the link below to download the full Press Release:-

MRCF Invests AU$1m in Antibiotics Start-Up Auspherix